NASDAQ:VVUS VIVUS (VVUS) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free VVUS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.26▼$0.4752-Week Range N/AVolume2.03 million shsAverage Volume1.44 million shsMarket Capitalization$7.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get VIVUS alerts: Email Address Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About VIVUS Stock (NASDAQ:VVUS)VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.Read More Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. VVUS Stock News HeadlinesJanuary 8, 2024 | markets.businessinsider.comVIVUS Provides Update on Pipeline and Program MilestonesMay 25, 2023 | it.tmcnet.comMetaview announces Answers, the world's first conversational AI for the interview processApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. October 2, 2022 | marketwatch.comWhy aren’t new drugs that can help you lose weight more widely used? - MarketWatchOctober 2, 2022 | morningstar.com'There's no way that patients are going to be able to afford that.' Why aren't new drugs that can help you lose weight more widely used? - MorningstarSeptember 23, 2022 | finance.yahoo.comErectile Dysfunction Drugs Market to Surpass Around USD 4079.9 Million by 2028, Says Brandessence Market Research - Yahoo FinanceSeptember 16, 2022 | streetinsider.comForm DEF 14A Catalent, Inc. For: Oct 27 - StreetInsider.comSeptember 9, 2022 | globenewswire.comObesity Management Market Expanding at an Impressive CAGR - GlobeNewswireApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. August 26, 2022 | finance.yahoo.comGlobal Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - Yahoo FinanceAugust 26, 2022 | prnewswire.comGlobal Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - PR NewswireAugust 17, 2022 | stockhouse.com2022-08-15 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - StockhouseAugust 15, 2022 | streetinsider.comPetros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - StreetInsider.comAugust 11, 2022 | finance.yahoo.comKaléo Announces Executive Appointments and New Government Business Unit - Yahoo FinanceAugust 5, 2022 | marketscreener.comIcahn Enterprises L P : Reports Second Quarter 2022 Financial Results - Form 8-K - Marketscreener.comAugust 2, 2022 | benzinga.comGlobal Cystic Fibrosis Market Report 2022-2030: CFTR Modulators Segment to Dominate the Market - BenzingaJuly 31, 2022 | businesswire.comGlobal Cystic Fibrosis Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts 2020-2030 - ResearchAndMarkets.com - Business WireJuly 26, 2022 | globenewswire.comGlobal Achondroplasia Market to Surpass US$ 1100.97 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswireJuly 14, 2022 | fortune.comThe best stock investing strategy for 2022: Don’t buy the dip, buy the dividend - FortuneJuly 5, 2022 | finance.yahoo.comBioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - Yahoo FinanceJuly 5, 2022 | streetinsider.comBioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - StreetInsider.comJune 8, 2022 | benzinga.comOverweight Treatment Market estimated to surge ahead at a CAGR of 7.9% by the end of 2032 - Persistence M - BenzingaMay 16, 2022 | stockhouse.com2022-05-16 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - StockhouseMay 6, 2022 | fool.comIcahn Enterprises (IEP) Q1 2022 Earnings Call Transcript - The Motley FoolMay 3, 2022 | gurufocus.comPetros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GuruFocus.comMay 3, 2022 | globenewswire.comPetros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GlobeNewswireApril 27, 2022 | gurufocus.comPetros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - GuruFocus.comSee More Headlines Receive VVUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2020Today4/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VVUS CUSIP92855110 CIK881524 Webwww.vivus.com Phone(650) 934-5200FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,500,000.00 Net Margins-39.28% Pretax MarginN/A Return on EquityN/A Return on Assets-12.18% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.28 Sales & Book Value Annual Sales$69.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($6.50) per share Price / BookN/AMiscellaneous Outstanding Shares17,867,000Free FloatN/AMarket Cap$7.33 million OptionableOptionable Beta-0.84 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesJohn P. AmosChief Executive Officer & DirectorMark K. OkiChief Financial & Accounting Officer, Senior VPSantosh T. VargheseChief Medical Officer & Senior Vice PresidentTed BromanVice President-Chemistry, Manufacturing & ControlTracy GuoVice President-FinanceKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXeFFECTOR TherapeuticsNASDAQ:EFTRChemomab TherapeuticsNASDAQ:CMMBCan-Fite BioPharmaNYSE:CANFTrevenaNASDAQ:TRVNView All Competitors VVUS Stock Analysis - Frequently Asked Questions How were VIVUS's earnings last quarter? VIVUS, Inc. (NASDAQ:VVUS) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter. When did VIVUS's stock split? Shares of VIVUS reverse split on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of VIVUS own? Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Novavax (NVAX), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Amarin (AMRN), Geron (GERN) and Idera Pharmaceuticals (IDRA). This page (NASDAQ:VVUS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
